Abstract 853: Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients
Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Jeff Hall, Douglas B. Johnson(Vanderbilt University Medical Center), Bashar Dabbas(Lineage Cell Therapeutics (United States)), Shabnam Tangri(Navidea Biopharmaceuticals (United States)), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Christine Vaupel(Navidea Biopharmaceuticals (United States)), Jelveh Lameh(Lineage Cell Therapeutics (United States)), Ju‐Young Kim(Lineage Cell Therapeutics (United States)), Justin Cates(Vanderbilt University Medical Center)
Cited by 2
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k